AINHOA MAIZ

Ainhoa Maiz stands as a pivotal Principal at Section 32, a distinguished venture capital firm renowned for its strategic investments in the healthcare and life sciences sectors. In her capacity, Ainhoa is instrumental in shaping the firm's investment thesis, meticulously identifying and championing early-stage and growth-stage companies that promise to revolutionize medicine and improve human health.

At Section 32, Ainhoa Maiz's role encompasses a broad spectrum of responsibilities, from rigorous due diligence and market analysis to active engagement with portfolio companies. She works closely with founders and management teams, offering strategic guidance, operational support, and leveraging Section 32's extensive network to accelerate growth and market penetration. Her contributions are vital in fostering a portfolio of innovative companies that are developing cutting-edge therapeutics, diagnostics, medical devices, and digital health solutions.

Her investment focus is sharply honed on areas within healthcare and life sciences that demonstrate high potential for disruptive innovation and significant patient impact. This includes, but is not limited to, novel biotechnologies, precision medicine, genomics, AI-driven drug discovery platforms, advanced medical devices, and digital health tools that enhance patient engagement and care delivery. Ainhoa is particularly interested in ventures that combine scientific rigor with strong commercial viability, seeking out teams with deep expertise and a clear vision for addressing critical healthcare challenges.

While specific details of her career background prior to Section 32 are not publicly detailed, her role as a Principal at such a prominent firm suggests a robust foundation in science, business, or finance, likely coupled with significant experience in the biotechnology, pharmaceutical, or venture capital industries. Professionals in her position typically possess a keen analytical mind, an ability to navigate complex scientific landscapes, and a deep understanding of market dynamics and regulatory pathways within the healthcare ecosystem. This expertise enables her to effectively evaluate the scientific merit, market potential, and operational capabilities of prospective investments.

Through her work at Section 32, Ainhoa Maiz contributes to the firm's mission of building a healthier future by investing in the most promising innovations. Her dedication helps ensure that groundbreaking scientific discoveries translate into tangible solutions that benefit patients worldwide. She is a key player in the venture capital community, committed to fostering the next generation of healthcare leaders and technologies.